New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
07:10 EDTNLNKNewLink Genetics weakness creates buying opportunity, says Cantor
Cantor reports that NewLink's stock has been pressured since the announcement of the continuation of the IMPRESS trial of its pancreatic cancer drug to the next review point. The firm expected this to occur but notes that the timing of the continuation has raised concerns about survival rates and the possibility that the control arm is performing better than expected. Cantor thinks it's too early to be concerned about these issues, and raised its price target on the shares to $34 from $30 while keeping a Buy rating on the stock.
News For NLNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
14:05 EDTNLNKPatient at UC Davis Medical center tests negative for Ebola, WSJ reports
Subscribe for More Information
January 29, 2015
13:51 EDTNLNKPotential Ebola patient being treated at UC Davis Medical Center, KCRA says
Subscribe for More Information
January 25, 2015
13:57 EDTNLNKUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 23, 2015
06:39 EDTNLNKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use